NasdaqGS:CTKBLife Sciences
Can Cytek Biosciences' (CTKB) Steady Outlook Offset Its Shift to Losses?
Earlier this month, Cytek Biosciences reported third-quarter 2025 earnings, showing revenue of US$52.29 million and a net loss of US$5.48 million compared to net income in the prior year, and reaffirmed its full-year revenue guidance of US$196 million to US$205 million.
This combination of improved quarterly revenue but a swing to quarterly and year-to-date losses provided investors with contrasting signals about Cytek’s ongoing financial health and outlook.
We’ll review how the...